Employees: 03 (2023.0)Legal category: 5485Size: PMECreation date: 2014-12-08 (11 years)Status: ActiveBusiness sector: Commerce de détail de produits pharmaceutiques en magasin spécialiséLocation: MONTREVAULT-SUR-EVRE (49110), Maine-et-Loire
Les données financières de cette entreprise sont partiellement disponibles (liasse simplifiée ou données confidentielles). Certaines sections ne sont pas affichées.
PHARMACIE GINKGOPHARMA : revenue, balance sheet and financial ratios
PHARMACIE GINKGOPHARMA is a French company
founded 11 years ago,
specialized in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé.
Based in MONTREVAULT-SUR-EVRE (49110),
this company of category PME
shows in 2025 a net income positive of 216 k€.
Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Financial history - PHARMACIE GINKGOPHARMA (SIREN 808626600)
Indicator
2025
2024
2023
2022
2021
2020
2019
2018
2016
Revenue
N/C
N/C
N/C
N/C
N/C
N/C
N/C
N/C
N/C
Net income
215 670 €
72 441 €
111 277 €
131 606 €
139 114 €
124 149 €
90 472 €
157 516 €
157 695 €
EBITDA
N/C
N/C
N/C
N/C
N/C
N/C
N/C
N/C
N/C
Net margin
N/C
N/C
N/C
N/C
N/C
N/C
N/C
N/C
N/C
Revenue and income statement
In 2025, PHARMACIE GINKGOPHARMA generates positive net income of 216 k€. Net income represents the final profit after all expenses (operating, financial, exceptional) and corporate tax. Change over 2016-2025: 158 k€ -> 216 k€.
Net income (2025)
?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax
215 670 €
Loading income statement...
Income statement
Item
Amount
% Revenue
Change
The detailed income statement is not available for this company (simplified accounts or confidential data).
Chart evolution
Show :
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Assets
Loading data...
Item
Gross
Deprec.
Net
%
Change
Assets balance sheet data not available for this company
Liabilities
Loading data...
Item
Year
%
Change
Liabilities balance sheet data not available for this company
Solvency and debt ratios
The debt ratio (= Financial debt / Equity x 100) stands at 35%. Debt remains under control: the company retains capacity to raise new debt if needed. Financial autonomy (= Equity / Total assets x 100) reaches 69%. This high autonomy means the company finances most of its assets through equity, a sign of strength.
Debt ratio (2025)
?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low 50-100% : Moderate > 100% : High
35.213%
Financial autonomy (2025)
?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy 20-30% : Average < 20% : Low
69.075%
Asset age ratio (2025)
?
Asset age ratio
Definition
Measures the degree of wear of tangible assets.
Formula
Accumulated depreciation / Gross fixed assets x 100
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Indicator
2016
2018
2019
2020
2021
2022
2023
2024
2025
Debt ratio
0.0
144.887
116.767
73.601
48.16
38.456
27.222
22.14
35.213
Financial autonomy
17.954
37.732
43.252
53.162
62.577
64.3
72.49
74.987
69.075
Repayment capacity
None
None
None
None
None
None
None
None
None
Cash flow / Revenue
None%
None%
None%
None%
None%
None%
None%
None%
None%
Sector positioning
Debt ratio
35.212025
2023
2024
2025
Q1: 13.71
Med: 49.76
Q3: 129.07
Good+11 pts over 3 years
In 2025, the debt ratio of PHARMACIE GINKGOPHARMA (35.21) ranks below the median of the sector. This ratio measures the weight of debt relative to equity. This controlled position reflects prudent management.
Financial autonomy
69.08%2025
2023
2024
2025
Q1: 33.42%
Med: 53.71%
Q3: 72.08%
Good
In 2025, the financial autonomy of PHARMACIE GINKGOPHARMA (69.1%) ranks above the median of the sector. This ratio represents the share of equity in total financing. This comfortable position offers an appreciable safety margin.
Liquidity ratios
The liquidity ratio (= Current assets / Current liabilities) stands at 543.27. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.
Liquidity ratio (2025)
?
Liquidity ratio
Definition
Ability to meet short-term debts with current assets.
Formula
Current assets / Current liabilities
Interpretation
> 1.5 : Very good 1-1.5 : Fair < 1 : Liquidity risk
Visualisation créée via abddaf.fr Sources : INPI & BCE - Retraitements : Ministère de l'économie
Indicator
2016
2018
2019
2020
2021
2022
2023
2024
2025
Liquidity ratio
489.983
500.69
608.154
466.16
486.981
347.809
474.48
377.31
543.275
Interest coverage
None
None
None
None
None
None
None
None
None
Sector positioning
Liquidity ratio
543.272025
2023
2024
2025
Q1: 131.03
Med: 182.29
Q3: 258.7
Excellent
In 2025, the liquidity ratio of PHARMACIE GINKGOPHARMA (543.27) ranks in the top 25% of the sector. This ratio measures the ability to cover short-term debt with current assets. A ratio above 1 ensures comfortable coverage of short-term maturities.
Positioning of PHARMACIE GINKGOPHARMA in its sector
Comparison with sector Commerce de détail de produits pharmaceutiques en magasin spécialisé
Valuation estimate
Based on 277 transactions of similar company sales
in 2025,
the value of PHARMACIE GINKGOPHARMA is estimated at
3 425 943 €
(range 2 324 861€ - 5 375 777€).
This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.
Estimated enterprise value2025
277 transactions
2324k€3425k€5375k€
3 425 943 €Range: 2 324 861€ - 5 375 777€
NAF 5 année 2025
Valuation method used
Net Income Multiple
215 670 €
×
15.9x
=3 425 944 €
Range: 2 324 862€ - 5 375 777€
Only this financial indicator is available for this company.
Valuation evolution
Visualisation creee via abddaf.fr Sources : BODACC & INPI
How is this estimate calculated?
This estimate is based on the analysis of 277 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.
EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
Net Income Multiple: Relevant for mature companies with stable results.
This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).
Similar companies (Commerce de détail de produits pharmaceutiques en magasin spécialisé)
Compare PHARMACIE GINKGOPHARMA with other companies in the same sector:
Frequently asked questions about PHARMACIE GINKGOPHARMA
What is the revenue of PHARMACIE GINKGOPHARMA ?
The revenue of PHARMACIE GINKGOPHARMA is not publicly disclosed (confidential accounts filed with INPI).
Is PHARMACIE GINKGOPHARMA profitable?
Yes, PHARMACIE GINKGOPHARMA generated a net profit of 216 k€ in 2025.
Where is the headquarters of PHARMACIE GINKGOPHARMA ?
The headquarters of PHARMACIE GINKGOPHARMA is located in MONTREVAULT-SUR-EVRE (49110), in the department Maine-et-Loire.
Where to find the tax return of PHARMACIE GINKGOPHARMA ?
The tax return of PHARMACIE GINKGOPHARMA is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
In which sector does PHARMACIE GINKGOPHARMA operate?
PHARMACIE GINKGOPHARMA operates in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé (NAF code 47.73Z). See the 'Sector positioning' section above to compare the company with its competitors.
Item evolution
Rotate your phone to landscape mode to view the chart